{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:49:15Z","timestamp":1793828955323,"version":"4.6.1"},"reference-count":21,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Graft-versus-host disease (GVHD) is one of the leading causes of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (allo-HCT). Posttransplant cyclophosphamide (PTCy) has shown promise in managing GVHD. However, cyclophosphamide has known cardiac toxicity, and few studies have evaluated the cardiac toxicities that arise after PTCy. We completed a retrospective analysis of patients who underwent matched-donor allo-HCT at our institution and who received PTCy- or non-PTCy\u2013based GVHD prophylaxis, with the goal of determining the incidence of cardiac toxicities up to 100 days after allo-HCT. We included 585 patients in our analysis and found that 38 (6.5%) experienced cardiac toxicity after allo-HCT. The toxicities included arrhythmias (n = 21), heart failure (n = 14), pericardial effusion (n = 10), and myocardial infarction or ischemia (n = 7). Patients who received PTCy had a 7.4% incidence of cardiac toxicity, whereas non-PTCy recipients had an incidence of 5.8% (P = .4). We found that age &amp;gt;55 years (P = .02) and a history of hypertension (P = .01), arrhythmia (P = .003), diabetes (P = .04), and cardiac comorbidities (P &amp;lt; .001) were significant predictors of cardiac toxicity, whereas none of the preparative and GVHD prophylaxis regimens were predictive. From these findings, we proposed the use of a Cardiac Risk Stratification Score to quantify the risk of cardiac toxicity after allo-HCT. We found that a higher score correlated with an incidence of cardiac toxicity. Furthermore, the development of cardiac toxicity was associated with worse 1-year overall survival (OS) and NRM. The use of PTCy was associated with improvements in 1-year OS and NRM rates.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004846","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T09:13:33Z","timestamp":1633079613000},"page":"5599-5607","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":69,"title":["Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7422-8951","authenticated-orcid":false,"given":"Jason","family":"Yeh","sequence":"first","affiliation":[{"name":"Division of Pharmacy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Whited","sequence":"additional","affiliation":[{"name":"Division of Pharmacy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima M.","family":"Saliba","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Banchs","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shpall","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-5037","authenticated-orcid":false,"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-2224","authenticated-orcid":false,"given":"Uday","family":"Popat","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"issue":"6","key":"2021122016304044200_B1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.bbmt.2014.02.012","article-title":"Late cardiovascular complications after hematopoietic cell transplantation","volume":"20","author":"Chow","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2021122016304044200_B2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/10428194.2017.1361027","article-title":"Myeloablative busulfan\/cytoxan conditioning versus reduced-intensity fludarabine\/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia","volume":"59","author":"Dhere","year":"2018","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2021122016304044200_B3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med."},{"issue":"6","key":"2021122016304044200_B4","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00277-019-03673-3","article-title":"Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study","volume":"98","author":"Soltermann","year":"2019","journal-title":"Ann Hematol."},{"issue":"3","key":"2021122016304044200_B5","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol."},{"issue":"4","key":"2021122016304044200_B6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bbmt.2014.08.014","article-title":"Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease","volume":"21","author":"Al-Homsi","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"10","key":"2021122016304044200_B7","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.30534","article-title":"Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation","volume":"123","author":"Lin","year":"2017","journal-title":"Cancer."},{"issue":"10","key":"2021122016304044200_B8","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbmt.2009.06.001","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction","volume":"15","author":"Qazilbash","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"issue":"8","key":"2021122016304044200_B9","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3324\/haematol.13514","article-title":"Cardiovascular disease after hematopoietic cell transplantation--lessons learned","volume":"93","author":"Armenian","year":"2008","journal-title":"Haematologica."},{"issue":"6","key":"2021122016304044200_B10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"issue":"16","key":"2021122016304044200_B11","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood."},{"issue":"31","key":"2021122016304044200_B12","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol."},{"issue":"1","key":"2021122016304044200_B13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","article-title":"Posttransplant cyclophosphamide for GVHD prophylaxis in HLA matched sibling or matched-unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J Hematol Oncol."},{"key":"2021122016304044200_B14","article-title":"Common Terminology Criteria for Adverse Events, Version 4.0 (version 4.03)","author":"US Department of Health and Human Services","year":"2009"},{"issue":"8","key":"2021122016304044200_B15","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"So","year":"2005","journal-title":"Blood."},{"key":"2021122016304044200_B16","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/bmt.2015.92","article-title":"HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide","volume":"50","author":"Fuchs","year":"2015","journal-title":"Bone Marrow Transplant."},{"issue":"18","key":"2021122016304044200_B17","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood-2014-11-608406","article-title":"Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation","volume":"125","author":"Roberto","year":"2015","journal-title":"Blood."},{"issue":"6","key":"2021122016304044200_B18","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bbmt.2014.11.676","article-title":"Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation","volume":"21","author":"Storek","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"9","key":"2021122016304044200_B19","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.bbmt.2019.05.020","article-title":"Characterization of viral infections after antithymocyte globulin-based conditioning in adults undergoing allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Figgins","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2021122016304044200_B20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-155-1-201107050-00004","article-title":"Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation","volume":"155","author":"Chow","year":"2011","journal-title":"Ann Intern Med."},{"issue":"12","key":"2021122016304044200_B21","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.bbmt.2020.08.029","article-title":"A new standard in graft-versus-host disease prophylaxis? An introduction to Blood and Marrow Transplant Clinical Trials Network 1703","volume":"26","author":"DeFilipp","year":"2020","journal-title":"Biol Blood Marrow Transplant."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/24\/5599\/1853824\/advancesadv2021004846.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/24\/5599\/1853824\/advancesadv2021004846.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T16:31:58Z","timestamp":1640017918000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/24\/5599\/477108\/Cardiac-toxicity-after-matched-allogeneic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":21,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021,12,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004846","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]}}}